{"filings":[{"id":3550321,"accession_number":"0001193125-26-425684","cik":1882782,"company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","form_type":"8-K","filed_at":"2026-10-20T11:00:21+00:00","items":["7.01","9.01"],"status":"ready","headline":"Odyssey OD-001 Phase 2a UC induction: 27% clinical remission at 20mg BID; primary endpoint met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: mean 2.4-point reduction in modified Mayo score at Week 12 across 56 efficacy-evaluable patients (p<0.001).","20 mg BID (n=41): clinical remission 27%, clinical response 61%, symptomatic remission 49%; 10 mg BID (n=15): 20%, 40%, 27%.","At 20 mg BID, hsCRP and circulating neutrophils fell significantly and serum albumin rose; remission was 16% in MES 3 patients (n=19) and 29%/23% in therapy-naive/experienced.","No serious adverse events, serious infections, treatment-related discontinuations or liver-function abnormalities; 3 drug-related AEs at 20 mg BID (2 fevers, 1 headache).","Plans randomized placebo-controlled Phase 2b monotherapy and Phase 2a OD-001 plus vedolizumab combo; topline induction data expected H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":839704694.2156,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2750687,"accession_number":"0001193125-26-385477","cik":1882782,"company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","form_type":"8-K","filed_at":"2026-09-08T23:10:19+00:00","items":["7.01","9.01"],"status":"ready","headline":"Odyssey Therapeutics posts corporate presentation; no financial details in 8-K","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Odyssey Therapeutics posted a corporate presentation on its investor relations website on September 8, 2026.","The 8-K filing only announces the posting; the presentation's content is not included in the filing.","No financial results, guidance, or material business developments are disclosed in the filing.","Investors should review the presentation on the company's IR page for any updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":839704694.2156,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2033492,"accession_number":"0001193125-26-331512","cik":1882782,"company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","form_type":"8-K","filed_at":"2026-08-04T11:00:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Odyssey Therapeutics Q2 2026 net loss $52.8M; cash $433.1M; OD-001 data at UEG Week","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $52.8M for Q2 2026 vs $41.2M in Q2 2025; adjusted net loss (non-GAAP) $38.4M.","Cash, cash equivalents and marketable securities $433.1M as of June 30, 2026; expected to fund operations into 2H 2028.","R&D expenses $36.2M (up from $30.2M); G&A $10.5M (down from $13.2M).","OD-001 Phase 2a data accepted for oral presentation at UEG Week in October; Phase 2b monotherapy and Phase 2a combo with vedolizumab expected to initiate in 2H 2026.","OD-002 (SLC15A4 inhibitor) CTA filing expected in 2H 2026; Phase 1/2a trial initiation in 1H 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":839704694.2156,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1204917,"accession_number":"0001193125-26-278581","cik":1882782,"company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","form_type":"8-K","filed_at":"2026-06-23T12:45:40+00:00","items":["7.01","9.01"],"status":"ready","headline":"Odyssey Therapeutics posts June 2026 corporate presentation on website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1; no specific financial or clinical updates provided in filing text.","No detailed content available; summary based solely on filing metadata.","Ticker ODTX; presentation posted on investors.odysseytx.com.","Event reported under Regulation FD; no earnings or material agreements disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":839704694.2156,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1112597,"accession_number":"0001193125-26-274291","cik":1882782,"company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","form_type":"8-K","filed_at":"2026-06-17T20:45:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Odyssey Therapeutics Q1 net loss $38.3M; pro-forma cash $464M; positive OD-001 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and securities $175.7M at Mar 31, 2026; pro-forma cash $464.4M after IPO net proceeds of $288.7M.","Net loss of $38.3M for Q1 2026, comparable to $38.4M in Q1 2025.","R&D expenses $32.3M (down $6.5M YoY); G&A $7.4M (down $0.6M YoY).","Phase 2a proof-of-concept for OD-001: 27% clinical remission, 61% clinical response in UC.","Plan to launch Phase 2b monotherapy and Phase 2a combo trial with vedolizumab in H2 2026; data H2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":839704694.2156,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":13883,"accession_number":"0001193125-26-216899","cik":1882782,"company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","form_type":"8-K","filed_at":"2026-05-11T20:30:18+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Odyssey Therapeutics raises $25M from TPG affiliate in private placement concurrent with IPO at $18/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 1,388,889 shares of common stock at $18.00 per share for total proceeds of $25,000,002.","Placement closed concurrently with the IPO on May 11, 2026; shares are registrable under existing Investor Rights Agreement.","J.P. Morgan, TD Securities, Cantor Fitzgerald, Wedbush, Oppenheimer acted as placement agents; fee of 7% of purchase price.","Company filed amended certificate of incorporation and bylaws effective upon IPO closing on May 11, 2026.","TPG LSI Rise Orazio II, L.P., an affiliate of an existing stockholder, is the purchaser."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":839704694.2156,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}